Latest Headlines

Latest Headlines

Roche inks contract with the Netherlands for frontline HPV testing

Roche won a contract in the Netherlands to provide its HPV test for primary screening of cervical cancer through the country's national cervical cancer screening program, a milestone for the company more than a year after its scored FDA approval for its diagnostic for frontline HPV testing.

Hong Kong drugstores attract Chinese customers for cancer, hep C drugs

Many shoebox-sized drugstores in Hong Kong are magnets for mainland Chinese seeking access to cutting-edge oncology and hepatitis C treatments without a prescription because they are either highly expensive or not available at home in the latest twist of cross-border healthcare buying, Bloomberg reports.

Roche leads the pack at ECTRIMS with standout data on new MS drug

Roche was unquestionably the big winner at last week's multiple sclerosis confab in Europe: Its forthcoming therapy ocrelizumab now boasts data in primary progressive and relapsing remitting forms of the disease, and the drug beat the established therapy Rebif in two of those trials. The company is planning regulatory filings early next year. 

Roche picks up a new autoimmune drug with $580M Adheron deal

Roche is investing in an early-stage project that takes a novel approach to treating autoimmune diseases, agreeing to pay up to $580 million for California's Adheron Therapeutics.

Is Google a competitor or partner to Big Pharma? Roche's CEO doesn't know, yet

The advance of Google and other tech firms into life sciences has given drug developers a new source of partners with complementary skills but also raised an awkward question: Long term, are these companies allies or rivals? For Roche CEO Severin Schwan, the answer is still unclear.

Roche looks to shake up the MS market with some promising Phase III data

Roche's much-hyped multiple sclerosis treatment ocrelizumab kept up its momentum with the release of detailed late-stage data, burnishing hopes the injected drug is a blockbuster in the making.

Experts push for trials to evaluate Roche, GSK flu drugs' pandemic potential

Critics have long questioned the effectiveness of Roche and GlaxoSmithKline's flu drugs, asking whether their benefits justify the estimated $2 billion spent to stockpile them for potential epidemics. Now, heading into flu season, scientists have an answer: No one knows. 

Roche CEO: Big Data needs Big Pharma, and vice versa

Count Roche CEO Severin Schwan among those who see digital partnerships as the way Big Pharma can finally take advantage of Big Data. And to his mind, tech companies really need to take advantage of pharma's expertise if they want to get ahead in healthcare.

Shanghai-based biotech Ark Biosciences successfully completes PhI on RSV candidate

Venture-backed Ark Biosciences has successfully completed a Phase I clinical trial of work on anti-respiratory syncytial virus (RSV) candidate AK0529, hitting a key milestone for the respiratory viral infection and viral hepatitis focused company.

U.K. patient group demands government override Roche's Kadcyla patents

Roche has been facing pricing pushback for its breast cancer drug Kadcyla in the U.K., with the country's cost watchdog nixing the med last year and the Cancer Drugs Fund recently rejecting it from its covered list. Now, patients are voicing their discontent, calling on Britain's health minister to override the company's Kadcyla patents and open the door for lower-priced copies.